# Efficacy and Safety on Prouk for STEMI Patients in China

Study · id `cardio:ct-nct02367976` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02367976](<https://clinicaltrials.gov/study/NCT02367976>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02367976

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 450 participants.

## Technical summary

Registry record NCT02367976. Randomized; single masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 450 participants (planned count; ClinicalTrials.gov record NCT02367976, source copy `cardio:ctgov-nct02367976-2015-02-25`, retrieved 2026-10-26)
- Start date: 2015-01 (registry gives no type) (ClinicalTrials.gov record NCT02367976, source copy `cardio:ctgov-nct02367976-2015-02-25`, retrieved 2026-10-26)
- Primary completion: 2016-12 (anticipated) (ClinicalTrials.gov record NCT02367976, source copy `cardio:ctgov-nct02367976-2015-02-25`, retrieved 2026-10-26)
- Completion: 2017-12 (anticipated) (ClinicalTrials.gov record NCT02367976, source copy `cardio:ctgov-nct02367976-2015-02-25`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02367976, source copy `cardio:ctgov-nct02367976-2015-02-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02367976-2015-02-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety on Prouk for STEMI Patients in China
- Condition: STEMI
- Intervention (Drug): rhprouk
- Lead sponsor: Suzhou RxD Biopharmaceutical Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)

## Provenance

Content hash: 223e106cd06c35c65bef912222a9bfeca79da1da228bcd47a4016a63ac0294e6
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
